Peter Moran
Angel Investor
San Francisco, United States
Peter Moran is a Member of the Board of Directors at Iterative Scopes. He attended Stanford University, Massachusetts Institute of Technology, MIT - Sloan School of Management, and Stanford University.
- Total investments:
- 37
- Last investment:
- Lead investor:
- 16%
Last updated:
For AI agents: llms.txt
Industries Peter Moran invests in
Stages Peter Moran invests in
Countries Peter Moran invests in
Round sizes
Round size
- Series A
- $4.3M–$16M
- Series B
- $10M–$30M
- Series C
- $15M–$630M
Investment Focus
Industry
- Health Care 5 (14%)
- Semiconductor 4 (11%)
- Medical 3 (8%)
- Electronics 3 (8%)
- Manufacturing 3 (8%)
Stage
- Series B 7 (19%)
- Series C 7 (19%)
- Series A 4 (11%)
- Seed 3 (8%)
- Funding Round 3 (8%)
Country
- United States 16 (43%)
- China 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sound Health
|
Sound Health uses acoustic resonance to provide nasal relief. Its current product is an app that scans the face to map the bone structure and then a headband that plays music at personalized frequencies for 10 minutes. The headband is off the shelf and the sound levels are akin to wearing earpods. It envisions the headband to be over-the-counter(OTC) so it’s easily accessible to patients, whether prescribed by doctors or not. | $7M / Seed / Jul 24, 2024 | |
Queer Spaces
|
Queer Spaces is building SPACES, a group chat platform for queer communities, and an app to serve the entirety of the LGBTQ+ spectrum. It’s a place for all queer people to connect over their favourite topics and interests, plan meetups and hang out. They can discover and join specific communities, fandoms, local teams and organizations, and closefriends, some public and others invite-only, all on a platform where they can safely be their true, authentic selves. | $1.1M / Convertible Note / Nov 09, 2022 | |
GPx
|
GPx is a biotech company that revolutionizes remote chronic disease management with bloodless blood tests. It is dedicated to transforming the standard of care of cardiorenal diseases and enabling patients to better understand their condition, much like the continuous glucose monitor has transformed diabetes care.The company was founded in 2020and is based in Boston, Massachusetts. | $3.3M / Seed / Sep 30, 2022 | |
Hava Health
|
Hava is a pre-clinical stage health company with a singular mission to reduce smoking-related illness and death. | $1.7M / Pre-Seed / Nov 13, 2019 | |
Augmedix
|
Augmedix empowers clinicians in all care settings to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decisionsupport.Incorporating data from millions of interactions, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes. | $19M / Series B / Oct 24, 2019 | |
|
Augmedix
|
Augmedix empowers clinicians in all care settings to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decisionsupport.Incorporating data from millions of interactions, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes. | $23M / Dec 08, 2016 | |
Rayvio
|
RayVio Corp. is an advanced health and hygiene company that delivers clean water and environments. RayVio helps protect billions from germs and creates new markets and revenue streams by enabling a new class of products. Its powerful and efficient UV LED technology can be integrated into a variety of applications, powering versatile on-demandsolutions that give consumers control over health without chemicals or costly consumables. To learn more, please visit www.rayvio.com. | $26M / Series B / Apr 26, 2016 | |
|
Augmedix
|
Augmedix empowers clinicians in all care settings to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decisionsupport.Incorporating data from millions of interactions, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes. | $17M / Apr 25, 2016 | |
Athos
|
The Athos mission is to help athletes train more effectively and reach their performance goals faster. Athos does this by bringing together the most relevant data and exercise science to deliver simple, actionable insights that allow coaches and athletes to get the most out of their training. | $35M / Series C / Nov 18, 2015 | |
LearnZillion
|
LearnZillion provides educators with curricular products for the new standards in digital and print. Its platform offers access to instructional materials for mathematics and literacy, as well as provides task-implementation guides for teachers that enable students and teachers to get benefited from each other through interactive learning.LearnZillion was founded in 2011 and is based in Washington, District of Columbia. | $13M / Series B / Sep 16, 2015 | |
| See all 37 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Peter Moran invest in?
Peter Moran invests primarily in Health Care, Semiconductor and Medical startups, most often at Series B and Series C stage. Most of the 37 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Peter Moran's check size?
Peter Moran typically joins rounds of $4.3M–$16M at Series A, $10M–$30M at Series B and $15M–$630M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Peter Moran participates in.
When did Peter Moran last invest?
The most recent investment recorded for Peter Moran closed in Jul 2024. Shizune tracks 37 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
